logo
Plus   Neg
Share
Email

Bristol Myers - MyoKardia Deal Receives U.S. Regulatory Approval

Bristol Myers Squibb (BMY) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with the company's tender offer to acquire MyoKardia Inc. (MYOK).

Expiration of the waiting period under the HSR Act satisfies one of the conditions necessary for the consummation of the transaction. The transaction remains subject to the tender of a majority of the outstanding shares of MyoKardia's common stock, as well as other customary closing conditions.

The tender offer will expire on November 16, 2020.

In early October, Bristol Myers Squibb agreed to acquire MyoKardia for $13.1 billion, or $225.00 per share in cash.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Electric Co. filed a lawsuit against Siemens Energy AG, accusing the German power distribution company of stealing trade secrets for gas turbines. Siemens Energy allegedly used the information to get at least nine contracts to supply gas turbines to public utilities, and also covered up improper business gains. Following a court ruling, the U.S. Food and Drug Administration postponed the effective date for tobacco manufacturing companies to display new health warnings on cigarette packets and in advertisements, by additional 90 days. The warnings with color images is to promote greater public understanding of the negative health consequences of smoking. JPMorgan Chase & Co (JPM) reported strong results in the fourth quarter of 2020, with net profit up 42% largely driven by credit reserve releases of $2.9 billion. The Group said it ended the year with a CET1 ratio of 13.1% and capital above $200 billion, providing with meaningful capacity to further...
Follow RTT